India and China are home to the largest diabetic populations globally, and the APAC region is expected to see a 120% increase by 2030. Factors such as poor diet, lack of exercise, and family history contribute to the alarming growth of type 2 diabetes mellitus, driving the huge diabetes drug market as well. Current estimates predict that the treatment market will increase from $6 billion in 2014 to over $10 billion by 2021. While key players in diabetes treatment such as insulin and metformin are expected to remain dominant in the market, novel therapeutics could also contribute to market growth. Pipeline molecules such as GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors already have a strong presence in current markets. Top candidates projected to reach Asian markets include Novo Nordisk’s OG-217SC due to it being the first oral formulation of GLP-1 agonist to reach the market.